Daiichi Sankyo Assumes Complete Control Of Ranbaxy, As Founders Exit
Executive Summary
MUMBAI, India - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of company management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon
You may also be interested in...
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
Abbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.